GALERA THERAPEUTICS, INC. (GRTX) News
Filter GRTX News Items
GRTX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest GRTX News From Around the Web
Below are the latest news stories about GALERA THERAPEUTICS INC that investors may wish to consider to help them evaluate GRTX as an investment opportunity.
Galera Reports Third Quarter 2023 Financial Results and Recent Corporate UpdatesFDA confirms need for new trial for avasopasem; GRECO trials with rucosopasem to be discontinued Company evaluating potential strategic options to optimize shareholder value MALVERN, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the third quarter ended Se |
Galera Announces Receipt of Type A Meeting Minutes and Strategic UpdateFDA confirms need for new trial for avasopasem for severe oral mucositis (SOM) GRECO-2 trial did not pass futility analysis; Company will discontinue both GRECO trials Company reviewing potential strategic alternatives to maximize shareholder value MALVERN, Pa., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayPre-market stock movers are a hot topic on Tuesday as investors seek out the latest news on the biggest gainers and losers this morning! |
Galera Schedules Type A Meeting with FDA to Discuss Next Steps for AvasopasemMALVERN, Pa., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that a Type A Meeting has been scheduled for September 28, 2023 with the U.S. Food and Drug Administration (FDA) regarding the Complete Response Letter (CRL) received for the Company’s New Drug Applica |
Galera to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceMALVERN, Pa., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11, 2023, at 4:3 |
All You Need to Know About Galera Therapeutics, Inc. (GRTX) Rating Upgrade to BuyGalera Therapeutics, Inc. (GRTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
Chevron upgraded, SolarEdge downgraded: Wall Street's top analyst callsChevron upgraded, SolarEdge downgraded: Wall Street's top analyst calls |
Galera Reports Second Quarter 2023 Financial Results and Recent Corporate UpdatesCompany received Complete Response Letter from FDA for avasopasem and intends to request Type A meeting with FDA to discuss potential next steps Cash runway extended into Q2 2024 in connection with reduction in workforce FDA granted orphan drug designation to rucosopasem for the treatment of pancreatic cancer Enrollment in GRECO trials with rucosopasem remains ongoing MALVERN, Pa., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical comp |
Biotech Stock Roundup: SAGE, GRTX Plunge on Setback, REGN to Buy DBTX & More NewsRegulatory updates from SAGE and Galera (GRTX) are in focus in the biotech sector. |
What Is Going on With Applied UV (AUVI) Stock Today?Applied UV (AUVI) stock is on the move Thursday as investors react to the disinfectant company getting $4 million in orders. |